Search Results - "Posadas, Tracey"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma

    45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma by Choueiri, Toni K, Powles, Thomas, Braun, David, Fong, Lawrence, George, Daniel, Haas, Naomi, McDermott, David F, Shuch, Brian, Gurney, Howard, Meehan, Robert, Posadas, Tracey, Wu, Sterling, Elfiky, Aymen, Motzer, Robert J

    Published in The oncologist (Dayton, Ohio) (06-08-2024)
    “…Abstract Background The PD-1 inhibitor pembrolizumab is approved as monotherapy for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Transfusion Requirements and Hospitalization during First Line Treatment Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Were Ineligible for Intensive Chemotherapy

    Transfusion Requirements and Hospitalization during First Line Treatment Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Were Ineligible for Intensive Chemotherapy by Bui, Cat N., Marshall, Thomas, Kamalakar, Rajesh, Posadas, Tracey, Potluri, Jalaja

    Published in Blood (29-11-2018)
    “…Background: Newly diagnosed acute myeloid leukemia (ND AML) patients (pts) ineligible for intensive chemotherapy have limited treatment options. Most commonly…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: